GET DAILY SIGNALSImmuneering (IMRX) Drops -15.8% Over 30 Days: Tracking the Biotech Stock’s Recent Moves
Key Takeaways
- IMRX fell roughly 15.8% over the last 30 days, from $5.07 on August 12, 2026, to $4.27 at the September 11, 2026 close.
- The decline unwound a mid-August rally that had carried shares to a peak near $5.33 on August 19, 2026.
- Over the trailing three months, the stock is roughly flat (up about 2%), having surged from near $4.19 in mid-June to a high above $5.50 in July before pulling back.
- Competitive headlines in pancreatic cancer, including the FDA approval of Revolution Medicines' Rasonque, weighed on sentiment in the short term.
- Immuneering held $182.7 million in cash and equivalents as of June 30, 2026, with runway into 2029 and pivotal Phase 3 topline data expected in mid-2028.
Immuneering (IMRX) at a Glance: Focus on Oncology Therapies
Immuneering Corporation is a Cambridge, Massachusetts-based late-stage oncology company developing therapies for broad populations of cancer patients. Its lead candidate, atebimetinib (IMM-1-104), is a dual-MEK inhibitor being evaluated in the global Phase 3 MAPKeeper 301 trial in combination with chemotherapy for first-line metastatic pancreatic cancer. A second program, envometinib (IMM-6-415), is in Phase 1/2a development for advanced solid tumors.
The company's platform centers on "Deep Cyclic Inhibition," a pharmacological approach designed to suppress tumor-driving MAPK signaling while allowing normal tissues to recover between doses, aiming to improve tolerability relative to traditional MEK inhibitors. Immuneering has clinical supply agreements with Regeneron (REGN) and Eli Lilly (LLY) to evaluate atebimetinib in combination studies. Investors follow the stock primarily for the Phase 3 pancreatic cancer data and the company's cash position, which supports an extended runway. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
IMRX Stock Price Action: 30-Day Slide Versus Three-Month View
Over the last 30 days, Immuneering shares declined approximately 15.8%, falling from $5.07 at the August 12, 2026 close to $4.27 at the September 11, 2026 close. The move reversed an intraday-period rally that had pushed the stock to a peak around $5.33 on August 19, followed by a steady drift lower through late August and early September, capped by a 6.6% single-session decline on September 11.
The longer three-month picture is more mixed. From a close of about $4.19 on June 12, 2026, the stock rallied sharply through late June and early July to a high above $5.50, consolidated near $5.30 into mid-August, and then pulled back. The result is a modest net gain of roughly 2% over the trailing quarter, masking substantial volatility that included a 52-week low near $3.86 and a 52-week high near $10.08 over the broader period.
What Shaped the Recent 30-Day Decline in IMRX
Several verified developments shaped the recent move. Early in the period, a wave of analyst activity supported the stock: H.C. Wainwright initiated coverage with a Buy rating and a $14.00 price target on August 6, UBS Group set a $14.00 target the same day, and Chardan Capital upgraded shares to "strong-buy" in early August. This coverage helped lift the stock toward its August 19 peak.
Sentiment then turned. Immuneering reported second-quarter results on August 5, posting a net loss of $0.27 per share, slightly wider than the $0.26 consensus estimate. Separately, the FDA approved Revolution Medicines' (RVMD) Rasonque (daraxonrasib) for previously treated metastatic pancreatic cancer, intensifying competitive attention around the pancreatic cancer space. Immuneering responded by reaffirming its distinct focus on the first-line setting, where atebimetinib is being studied, but the headlines contributed to a reassessment of near-term positioning. The subsequent September decline, including the sharp drop on September 11, reflected profit-taking and a lack of near-term catalysts rather than a single new negative event. From what I see, this competitive dynamic is important because it highlights how sector news can influence even well-positioned names.
Drivers Behind IMRX Performance Across the Quarter
The broader three-month trend was defined by a strong summer rally followed by a giveback. The stock climbed from roughly $4.19 in mid-June to above $5.50 in early July, supported by positive clinical commentary and analyst initiations, including Cantor Fitzgerald's Overweight rating and Mizuho's reiterated Outperform with a $12.00 price target following an updated atebimetinib dataset showing a 17.3-month median overall survival in first-line pancreatic cancer.
Operationally, the company dosed the first patient in the pivotal MAPKeeper 301 Phase 3 trial during June 2026 and named Andrew Gengos as Chief Financial Officer, effective July 16, 2026. These milestones reinforced the longer-term narrative even as shares consolidated in the $5.00 to $5.30 range through August. The subsequent pullback to the mid-$4 range reflects the typical volatility of a clinical-stage biotech trading between data readouts and financing expectations. I’m watching this closely as the company moves toward its next milestones.
Key Factors to Monitor for IMRX Going Forward
Looking ahead, the dominant catalyst is the MAPKeeper 301 Phase 3 trial for atebimetinib in first-line metastatic pancreatic cancer, with topline data expected in mid-2028. Enrollment progress, any protocol updates, and additional data presentations will be closely watched. Quarterly financial updates, including cash burn and runway commentary, matter given the company's reliance on its $182.7 million balance sheet.
Competitive developments in RAS-targeted therapies and the broader pancreatic cancer field could influence sentiment, as could analyst rating changes and institutional positioning. Macroeconomic conditions affecting the biotech sector, including interest rates and risk appetite for pre-revenue developers, also play a role. These factors are informational in nature and should not be interpreted as financial advice or a prediction of future performance.
Using Tickeron’s AI Tools for Deeper Market Insight
In my own research process, I often turn to Tickeron’s AI tools to cross-check patterns and compare opportunities across sectors. The Trending AI Robots page, for instance, surfaces top-performing automated strategies that can help put individual stock moves like this one in broader context. It’s a practical way to see which approaches are gaining traction without replacing core fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMRX in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 37 cases where IMRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Oscillator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where IMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on IMRX as a result. In 80 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for IMRX just turned positive on October 20, 2026. Looking at past instances where IMRX's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Following a +7.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in 220 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMRX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.248) is normal, around the industry mean (3.498). P/E Ratio (-3.957) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement